What a prescription drug label contains, section by section

Of the 28,609 generic prescription drug labels in FDA's public labeling dataset on Nov. 4, 2026, 16,386 were laid out in the format FDA adopted in 2006, with numbered sections and a half-page summary on top. Another 11,867, about 41 percent, still used the older layout, with a separate Precautions section and no summary box. Those counts come from GxRadar's queries of openFDA's drug labeling data⁹, which hold the structured product labeling files companies submit to FDA. GxRadar counted a label as the 2006 format when it had a Warnings and Precautions section, a heading old-format labels do not use.

Both kinds are legal. FDA's prescribing information resources page⁸ says prescribing information comes in two formats, the "Physician Labeling Rule" format and the "old" format, and that the newer one is required for drugs approved since June 2001 and for some older drugs that gained new uses after that.

The prescribing information is the long folded sheet in a stock bottle or carton, the document also posted on DailyMed. It is written for clinicians, but anyone can read it. This explainer walks through what the 2006 rule requires, section by section, what the 2015 pregnancy and lactation rule changed, and why so many generic labels look different from each other.

What the 2006 rule set up

FDA published the final rule on Jan. 24, 2006, as 71 FR 3922¹, effective June 30, 2006. It split prescribing information into three parts: Highlights of Prescribing Information, a Contents list, and the Full Prescribing Information. Highlights, except for any boxed warning, must fit in an amount of text that would fill half a page if printed in two columns of 8-point type on standard letter paper, under 21 CFR 201.57(d)(8)⁴.

The rule did not reach every drug. New applications had to use the format right away. Drugs approved in the five years before the effective date were phased in, and anything older could convert voluntarily, according to the implementation table in the Federal Register notice¹.

That last row explains much of the old-format share. For furosemide, a drug first approved decades before 2001, 94 of the 111 generic labels in openFDA use the old format; for prednisone, 232 of 239 do. FDA says it "strongly" encourages holders of old-format labeling to convert, on the same resources page⁸, because it believes the newer format reduces errors from misread information and works better with electronic prescribing tools.

Inside the Highlights box

Highlights opens with a verbatim warning that it does "not include all the information needed" to use the drug safely, followed by the brand and established names, the dosage form and route. Then comes the line "Initial U.S. Approval" with a four-digit year, under 21 CFR 201.57(a)⁴. On a generic, the year printed belongs to the ingredient's first US approval.

Next come any boxed warning, a list of Recent Major Changes, and short summaries of indications, dosage, dosage forms and strengths, contraindications, warnings and precautions, adverse reactions, drug interactions and specific populations. The dosage-forms summary must state the strength and "whether the product is scored," a detail GxRadar covers in its piece on scored tablets. Boxed warnings get their own explainer.

Two lines in Highlights matter to patients more than they might guess. One is the reporting statement, which must read "To report SUSPECTED ADVERSE REACTIONS, contact" the company or FDA, with FDA's phone number and web address. GxRadar explains where those reports go in its MedWatch explainer. The other is the revision date, which FDA describes⁷ as the month and year of the most recent change to the prescribing information.

The 17 numbered sections

Full Prescribing Information must use these headings in this order, according to 21 CFR 201.56(d)(1)³. Sections that do not apply can be left out, but the numbers stay fixed, so section 8 is always Use in Specific Populations.

Section 11 is where a reader finds the inactive ingredients; FDA's FAQ⁷ says Description covers the names, dosage form, route, chemistry and "a list of active and inactive ingredients." Section 16 holds the package descriptions and storage conditions, which GxRadar decodes in its storage explainer. In electronic labeling, each number in Highlights links to the matching section.

What the 2015 pregnancy and lactation rule changed

FDA published the Pregnancy and Lactation Labeling Rule on Dec. 4, 2014, as 79 FR 72064², and it took effect June 30, 2015. It "removes pregnancy letter categories – A, B, C, D and X," FDA's summary page⁵ says, and requires the label to be updated when information becomes outdated.

Section 8.1 Pregnancy now carries a Risk Summary, Clinical Considerations and Data, plus any pregnancy exposure registry. The old Nursing Mothers subsection became 8.2 Lactation, and 8.3 Females and Males of Reproductive Potential is new. Labeling for drugs approved on or after June 30, 2001, was phased in, while over-the-counter labels were untouched. Holders of applications approved before June 30, 2001, were required to remove the letter category within three years of the effective date, according to the final rule².

GxRadar's openFDA queries show the transition is incomplete in generic labeling. Among the 16,386 generic labels in the 2006 format, 12,630 have a pregnancy section that includes a "Risk Summary," the heading the 2015 rule introduced, while 4,544 still carry a Nursing Mothers section. Across all generic prescription labels, 4,900 still use the phrase "pregnancy category" in their pregnancy section. The data cannot show why any single label reads that way.

Generic labels, patient leaflets and where to read them

A generic label is supposed to match its reference brand's label, with limited exceptions, which is why its format usually follows the brand's. GxRadar's companion pieces cover how generic labeling must match the brand and carve-outs.

Prescribing information is only one piece of labeling. FDA's FAQ⁷ lists three kinds of patient labeling. Medication Guides are required in some cases and must be handed out with each fill. Patient Package Inserts are required for oral contraceptives and estrogen products. Instructions for Use cover products with complicated steps, such as patches or autoinjectors. GxRadar covers the first two in its guide to Medication Guides; the pharmacy's own sticker is a separate document, explained in how to read a prescription label.

DailyMed¹⁰, run by the National Library of Medicine, posts the labeling companies have most recently submitted; FDA's labeling resources page⁶ says DailyMed and FDALabel each search over 140,000 labeling documents. That version can differ from the last FDA-approved labeling on Drugs@FDA, the same page notes, because moderate changes such as a strengthened warning can go into use under a "Changes Being Effected" supplement while FDA reviews them. GxRadar's guide to looking up a drug on DailyMed shows how to find both.

Brand application holders are expected to review their prescribing information at least once a year for outdated content, FDA says on its resources page⁸, and to update it when it becomes inaccurate or misleading.